BioSpace News Archive

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer, will deliver a company presentation at the UBS Global Healthcare Conference on Tuesday, May 24 at 7:45 a.m. ET, in New York.

BrainsWay Ltd. a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported first quarter 2022 financial results and provided an operational update.

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), today announced that Prof. Matthias Liechti and Dr. Friederike Holze, MindMed collaborators at University Hospital Basel (UHB), have released positive topline data from a Phase 2 placebo-controlled investigator-initiated clinical trial evaluating LSD in the treatment of anxiety disorders.

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the first quarter ended March 31, 2022 (“Q1-F2022”).

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will be presenting at the UBS Global Healthcare Conference on May 25, 2022 at the Lotte New York Palace in New York, New York.

Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at upcoming investor conferences in May.

Pliant Therapeutics, Inc. announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in the following May investor conferences.

Spero Therapeutics, Inc. announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the 2022 RBC Capital Markets Global Healthcare Conference and the H.C. Wainwright Global Investment Conference, which are taking place May 17-18 and May 23-25, respectively.

Intercept Pharmaceuticals, Inc. today announced the first patient has been dosed in a Phase 2 study evaluating a fixed-dose combination of obeticholic acid (OCA) and bezafibrate (BZF).

Veru Inc. announced that in a Pre-EUA meeting held May 10, 2022, FDA has agreed that the efficacy and safety data from the completed Phase 3 clinical study in hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome are sufficient to support the submission of a request for Emergency Use Authorization.